BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36768380)

  • 1. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.
    Steinmann SM; Sánchez-Martín A; Tanzer E; Cigliano A; Pes GM; Simile MM; Desaubry L; Marin JJG; Evert M; Calvisi DF
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5'-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I.
    Wu C; Liu D; Zhang L; Wang J; Ding Y; Sun Z; Wang W
    Front Med; 2023 Jun; 17(3):476-492. PubMed ID: 36973570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-transmitted long non-coding RNA
    Wang J; Pu J; Zhang Y; Yao T; Luo Z; Li W; Xu G; Liu J; Wei W; Deng Y
    Aging (Albany NY); 2020 Jun; 12(12):11550-11567. PubMed ID: 32602848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Paip1 Expression as a Potential Prognostic Marker in Hepatocellular Carcinoma.
    Kim H; Jung W; Kim A; Kim HK; Kim BH
    In Vivo; 2020; 34(5):2491-2497. PubMed ID: 32871777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with
    Peters TL; Tillotson J; Yeomans AM; Wilmore S; Lemm E; Jiménez-Romero C; Amador LA; Li L; Amin AD; Pongtornpipat P; Zerio CJ; Ambrose AJ; Paine-Murrieta G; Greninger P; Vega F; Benes CH; Packham G; Rodríguez AD; Chapman E; Schatz JH
    Clin Cancer Res; 2018 Sep; 24(17):4256-4270. PubMed ID: 29844128
    [No Abstract]   [Full Text] [Related]  

  • 7. High intratumoral expression of eIF4A1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
    Gao C; Guo X; Xue A; Ruan Y; Wang H; Gao X
    Acta Biochim Biophys Sin (Shanghai); 2020 Mar; 52(3):310-319. PubMed ID: 32147684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of biological networks and the eukaryotic initiation factor 4A-3 gene as pivotal in hepatocellular carcinoma.
    Lin Y; Liang R; Mao Y; Ye J; Mai R; Gao X; Liu Z; Wainwright T; Li Q; Luo M; Ge L; Li Y; Zou D
    J Cell Biochem; 2020 Oct; 121(10):4094-4107. PubMed ID: 31898336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.
    Pott LL; Hagemann S; Reis H; Lorenz K; Bracht T; Herold T; Skryabin BV; Megger DA; Kälsch J; Weber F; Sitek B; Baba HA
    Oncotarget; 2017 Feb; 8(7):11950-11962. PubMed ID: 28060762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma.
    Zhu Q; Qiao GL; Zeng XC; Li Y; Yan JJ; Duan R; Du ZY
    Oncotarget; 2016 Aug; 7(31):49888-49901. PubMed ID: 27340783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
    Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
    J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
    Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
    Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
    Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
    Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.
    Wang C; Leavenworth J; Zhang C; Liu Z; Yuan KY; Wang Y; Zhang G; Wang S; Cui X; Zhang Y; Bae S; Zhou J; Wang L; Liu R
    Oncogene; 2022 May; 41(19):2778-2785. PubMed ID: 35361883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
    Wang W; Jia WD; Hu B; Pan YY
    Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
    Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.